Literature DB >> 24001358

The role of SOX11 in mantle cell lymphoma.

Ting-Xun Lu1, Jian-Yong Li, Wei Xu.   

Abstract

The mechanism of SOX11 function has been widely published recently mainly focused on histone modifications. Besides diagnostic value in mantle cell lymphoma (MCL), SOX11 has also prognostic significance. Although it can also be observed in a fraction of other T and B-cell lymphomas, a monoclonal antibody, called SOX11-C1, may improve the function of SOX11 in both diagnosis and prognosis evaluation. In addition, detection of modified SOX11 cDNA by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) has a higher sensitivity than traditional CCND1 examination in minimal residual disease (MRD) detection, which is an appealing option for predicting disease outcome and status.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CCND1; Mantle cell lymphoma; SOX11

Mesh：

Substances：

Year:  2013        PMID： 24001358     DOI： 10.1016/j.leukres.2013.07.039

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  10 in total

1.  Overexpression miR-211-5p hinders the proliferation, migration, and invasion of thyroid tumor cells by downregulating SOX11.

Authors:  Lei Wang; Yan-Feng Shen; Zhi-Min Shi; Xiao-Juan Shang; Dong-Ling Jin; Feng Xi
Journal:  J Clin Lab Anal       Date:  2017-07-13       Impact factor: 2.352

Review 2.  MicroRNAs as the critical regulators of cell migration and invasion in thyroid cancer.

Authors:  Amir Abbas Hamidi; Negin Taghehchian; Zahra Basirat; Amir Sadra Zangouei; Meysam Moghbeli
Journal:  Biomark Res       Date:  2022-06-04

3.  Detection of t(12;14)(p13;q32) in a patient with IGH-CCND1 negative mantle cell lymphoma resembling ultra-high risk chronic lymphocytic leukemia.

Authors:  Yi Miao; Rong Wang; Lei Fan; Hairong Qiu; Yujie Wu; Yaoyu Chen; Wei Xu; Jianyong Li
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

Review 4.  SOXC Genes and the Control of Skeletogenesis.

Authors:  Véronique Lefebvre; Pallavi Bhattaram
Journal:  Curr Osteoporos Rep       Date:  2016-02       Impact factor: 5.096

5.  Differential Expression of Sox11 and Bdnf mRNA Isoforms in the Injured and Regenerating Nervous Systems.

Authors:  Felix L Struebing; Jiaxing Wang; Ying Li; Rebecca King; Olivia C Mistretta; Arthur W English; Eldon E Geisert
Journal:  Front Mol Neurosci       Date:  2017-11-02       Impact factor: 5.639

6.  [Clinical analysis of the character and prognostic factors of 23 cases of mantle cell lymphoma].

Authors:  R Liang; Z Wang; M N Zhu; C X Hao; N Zhang; J H Wang; T Zhang; L Yang; H T Gu; B X Dong; Q X Bai; G X Gao; X Q Chen
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2016-06-14

7.  Cobblestone-area forming cells derived from patients with mantle cell lymphoma are enriched for CD133+ tumor-initiating cells.

Authors:  Daniel J Medina; Jeneba Abass-Shereef; Kelly Walton; Lauri Goodell; Hana Aviv; Roger K Strair; Tulin Budak-Alpdogan
Journal:  PLoS One       Date:  2014-04-10       Impact factor: 3.240

8.  Long non-coding RNA profile in mantle cell lymphoma identifies a functional lncRNA ROR1-AS1 associated with EZH2/PRC2 complex.

Authors:  Guangzhen Hu; Shiv K Gupta; Tammy P Troska; Asha Nair; Mamta Gupta
Journal:  Oncotarget       Date:  2017-05-17

Review 9.  Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents.

Authors:  Arati A Inamdar; Andre Goy; Nehad M Ayoub; Christen Attia; Lucia Oton; Varun Taruvai; Mark Costales; Yu-Ting Lin; Andrew Pecora; K Stephen Suh
Journal:  Oncotarget       Date:  2016-07-26

10.  Potential added value of a RT-qPCR method of SOX 11 expression, in the context of a multidisciplinary diagnostic assessment of B cell malignancies.

Authors:  Julien Magne; Alizée Jenvrin; Adrien Chauchet; Olivier Casasnovas; Anne Donzel; Laurence Jego; Bernard Aral; Julien Guy; Nathalie Nadal; Dewi Vernerey; Patrick Callier; Francine Garnache-Ottou; Christophe Ferrand
Journal:  Exp Hematol Oncol       Date:  2018-02-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.